Literature DB >> 10642267

Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study.

K Wachtell1, J N Bella, P R Liebson, E Gerdts, B Dahlöf, T Aalto, M J Roman, V Papademetriou, H Ibsen, J Rokkedal, R B Devereux.   

Abstract

Left ventricular (LV) hypertrophy and concentric remodeling have been defined by using a variety of indexation methods and partition values (PVs) for LV mass and relative wall thickness (RWT). The effects of these methods on the distribution of LV geometric patterns in hypertensive subjects remain unclear. Echocardiograms were obtained in 941 patients with stage I to III hypertension and LV hypertrophy by ECG. LV mass was calculated by using different methods of indexation for body size and different PVs to identify hypertrophy: LV mass/body surface area (g/m(2)) PV for men/women 116/104, 125/110, or 125/125; LV mass/height (g/m) PV 143/102 or 126/105; and LV mass/height(2.7) (g/m(2.7)) PV 51/51 or 49.2/46.7. RWT was calculated by either 2xend-diastolic posterior wall thickness (PWT)/end-diastolic LV internal dimension (LVID) or end-diastolic interventricular septum dimension+end-diastolic PWT/end-diastolic LVID. LV hypertrophy or remodeling was present in 63% to 86% of subjects, and LV hypertrophy was present in 42% to 77%. By any index, eccentric hypertrophy was the common LV geometric pattern. Use of interventricular septum dimension+PWT/LVID to calculate RWT slightly increased the prevalence of normal geometry and eccentric hypertrophy compared with the use of 2xPWT/LVID. Subjects with LV hypertrophy identified by only LV mass/height(2.7) PV 49.2/46.7 were more obese, whereas those identified by only LV mass/body surface area PV 116/104 were taller and thinner than those in the 2 concordant groups with or without LV hypertrophy by both criteria. By either criterion, there were no significant differences between different LV geometric patterns in clinical cardiovascular disease. Hypertensive patients with LV hypertrophy by ECG have a high prevalence of geometric abnormalities, especially eccentric hypertrophy, irrespective of method of indexation or PV. LV mass indexation by body surface area or height(2.7) identifies lean and obese subjects, respectively. We found no difference in prevalent cardiovascular disease in subjects identified by either criterion, suggesting a similar high risk.

Entities:  

Mesh:

Year:  2000        PMID: 10642267     DOI: 10.1161/01.hyp.35.1.6

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  29 in total

1.  Preclinical cardiac disease in nonalcoholic fatty liver disease with and without metabolic syndrome.

Authors:  Jasbir Makker; Hassan Tariq; Jonathan N Bella; Kishore Kumar; Chukwunonso Chime; Harish Patel; Muhammad Umar Kamal; Danial Shaikh; Vamshidhar Vootla; Bharat Bajantri; Umut Gomceli; Mohammad Alshelleh; Richard Peralta; Aiyi Zhang; Sridhar Chilimuri
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

2.  A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy.

Authors:  G S Bleumink; A F C Schut; M C J M Sturkenboom; J A M J L Janssen; J C M Witteman; C M van Duijn; A Hofman; B H Ch Stricker
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

3.  Heritability of left ventricular mass and other morphologic variables in Caribbean Hispanic subjects: the Northern Manhattan Family Study.

Authors:  Suh-Hang Hank Juo; Marco R Di Tullio; Hsiu-Fen Lin; Tanja Rundek; Bernadette Boden-Albala; Shunichi Homma; Ralph L Sacco
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

4.  Ethnicity and Left Ventricular Hypertrophy: Tools and Uncertainties.

Authors:  Daniel Piskorz
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-07-27

5.  The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus.

Authors:  A Dawson; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2005-08-11       Impact factor: 10.122

Review 6.  LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice.

Authors:  Anderson C Armstrong; Samuel Gidding; Ola Gjesdal; Colin Wu; David A Bluemke; João A C Lima
Journal:  JACC Cardiovasc Imaging       Date:  2012-08

Review 7.  Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy.

Authors:  P R Liebson; R D Serry
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

8.  Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction.

Authors:  Tomohiro Fujisaka; Shu-Ichi Fujita; Daichi Maeda; Kensaku Shibata; Hideaki Takahashi; Hideaki Morita; Yoshihiro Takeda; Takahide Ito; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  Heart Vessels       Date:  2017-06-06       Impact factor: 2.037

9.  The association of HIV infection with left ventricular mass/hypertrophy.

Authors:  Ather Mansoor; Elizabeth T Golub; Jack Dehovitz; Kathryn Anastos; Robert C Kaplan; Jason M Lazar
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

10.  Myocardial deformation in aortic valve stenosis: relation to left ventricular geometry.

Authors:  Dana Cramariuc; Eva Gerdts; Einar Skulstad Davidsen; Leidulf Segadal; Knut Matre
Journal:  Heart       Date:  2009-08-25       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.